中国药业2025，Vol.34Issue(8)：94-98,5.DOI:10.3969/j.issn.1006-4931.2025.08.022
脑血疏口服液佐治高血压脑出血临床评价
Clinical Evaluation of Naoxueshu Oral Liquid in the Adjuvant Treatment of Hypertensive Intracerebral Hemorrhage
摘要
Abstract
Objective To investigate the clinical efficacy of Naoxueshu Oral Liquid as an adjuvant therapy for hypertensive intracerebral hemorrhage(HICH),as well as its effects on serum levels of high-mobility group box-1 protein(HMGB-1),gelsolin(GSN),neuron-specific enolase(NSE)and patient prognosis.Methods A total of 104 HICH patients admitted to the hospital from January 2021 to June 2023 were selected and randomly divided into a control group and an observation group,with 52 patients in each group.Both groups received conventional symptomatic and supportive treatment,while the observation group was additionally administered Naoxueshu Oral Liquid for 4 weeks.Serum levels of HMGB-1,GSN,and NSE,as well as National Institutes of Health Stroke Scale(NIHSS)and Glasgow Outcome Scale(GOS)scores were compared between the two groups.Pearson correlation analysis was performed to assess the relationship between the three factor levels and the two scale scores.Clinical efficacy was compared between the two groups,and serum levels of the three factors were analyzed in patients with different treatment outcomes in the observation group.Receiver operating characteristic curve(ROC)analysis was used to evaluate the diagnostic value of the three serum factors for clinical efficacy in the observation group.Results After treatment,serum HMGB-1 and NSE levels as well as NIHSS scores significantly decreased,while GSN levels and GOS scores significantly increased in both two groups,and the observation group all significantly better than the control group(P<0.05).In the observation group,the levels of HMGB-1 and NSE were positively correlated with NIHSS score and negatively correlated with GOS score(P<0.05),while GSN level was negatively correlated with NIHSS score and positively correlated with GOS score(P<0.05).The total effective rate in the observation group was 86.54%,which was significantly higher than the 71.15%in the control group(P<0.05).Compared with the patients with ineffective treatment,the levels of HMGB-1 and NSE in the serum of the cured,markedly effective and effective patients were significantly decreased,and the level of GSN was significantly increased(P<0.05),and the change range of the cured patients was the largest.The sensitivity and specificity of serum three factor levels in the diagnosis of clinical efficacy were close to and both greater than 70%,and the combined diagnosis was higher.Conclusion The levels of serum three factors had high diagnostic value for the clinical efficacy of Naoxueshu Oral Liquid,with high sensitivity and specificity.The diagnostic efficacy of HMGB-1,GSN and NSE alone was similar,and the combined detection showed the highest diagnostic value(P<0.05).HMGB-1,GSN,and NSE showed similar diagnostic performance when tested individually,and the combined detection showed the highest diagnostic value(P<0.05).Naoxueshu oral liquid can significantly improve the degree of neurological deficits for HICH patients,enhance the clinical efficacy and improve the prognosis of patients.The reason may be related to the reduction of serum HMGB-1,NSE and the increase of GSN levels.关键词
高血压脑出血/脑血疏口服液/高迁移率族蛋白/凝溶胶蛋白/神经元特异性烯醇化酶/临床疗效/相关性/诊断价值Key words
hypertensive intracerebral hemorrhage/Naoxueshu Oral Liquid/high-mobility group box-1 protein/gelsolin/neuron-specific enolase/clinical efficacy/correlation/diagnostic value分类
医药卫生引用本文复制引用
齐洪武,刘岩松,曾维俊,郭洪均,郝紫建..脑血疏口服液佐治高血压脑出血临床评价[J].中国药业,2025,34(8):94-98,5.基金项目
河北省石家庄市科学技术研究与发展计划项目[201200753]. （）
